Asset Details
Do you wish to reserve the book?
Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus
Do you wish to request the book?
Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus
2019
Overview
Plasmacytoid DCs (pDC) produce large amounts of type I IFN (IFN-I), cytokines convincingly linked to systemic lupus erythematosus (SLE) pathogenesis. BIIB059 is a humanized mAb that binds blood DC antigen 2 (BDCA2), a pDC-specific receptor that inhibits the production of IFN-I and other inflammatory mediators when ligated. A first-in-human study was conducted to assess safety, tolerability, and pharmacokinetic (PK) and pharmacodynamic (PD) effects of single BIIB059 doses in healthy volunteers (HV) and patients with SLE with active cutaneous disease as well as proof of biological activity and preliminary clinical response in the SLE cohort.
A randomized, double-blind, placebo-controlled clinical trial was conducted in HV (n = 54) and patients with SLE (n = 12). All subjects were monitored for adverse events. Serum BIIB059 concentrations, BDCA2 levels on pDCs, and IFN-responsive biomarkers in whole blood and skin biopsies were measured. Skin disease activity was determined using the Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A).
Single doses of BIIB059 were associated with favorable safety and PK profiles. BIIB059 administration led to BDCA2 internalization on pDCs, which correlated with circulating BIIB059 levels. BIIB059 administration in patients with SLE decreased expression of IFN response genes in blood, normalized MxA expression, reduced immune infiltrates in skin lesions, and decreased CLASI-A score.
Single doses of BIIB059 were associated with favorable safety and PK/PD profiles and robust target engagement and biological activity, supporting further development of BIIB059 in SLE. The data suggest that targeting pDCs may be beneficial for patients with SLE, especially those with cutaneous manifestations.
ClinicalTrials.gov NCT02106897.
Biogen Inc.
Publisher
American Society for Clinical Investigation
Subject
/ Adult
/ Analysis
/ Antibodies, Monoclonal - administration & dosage
/ Antibodies, Monoclonal - immunology
/ Antibodies, Monoclonal - pharmacokinetics
/ Antigens
/ Blood
/ Cutaneous Lupus Erythematosus
/ Dendritic Cells - immunology
/ Disease
/ Female
/ Genes
/ Humans
/ Lectins, C-Type - antagonists & inhibitors
/ Lectins, C-Type - immunology
/ Lesions
/ Lupus
/ Lupus Erythematosus, Systemic - drug therapy
/ Lupus Erythematosus, Systemic - immunology
/ Lupus Erythematosus, Systemic - pathology
/ Male
/ Membrane Glycoproteins - antagonists & inhibitors
/ Membrane Glycoproteins - immunology
/ Receptors, Immunologic - antagonists & inhibitors
/ Receptors, Immunologic - immunology
/ Safety
/ Skin
